STAT3 plays a dual role in tumor inflammation and immunity by promoting the pro-tumor inflammatory pathway of nuclear factor-κb (NF-κb) and interleukin-6 (IL-6)-GP130-Janus kinase (JAK) and by inhibiting STAT1 and NF-κb-mediated Th1 antitumor immune responses (Yu et al., 2009; Gharibi et al., 2020). Here, NFKB1 is linked to neoplasm.